U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication- CompaniesWASHINGTON, Jan 9 (Reuters) - The U.S. Supreme Court on Monday turned away Pfizer Inc's (PFE.N) bid to revive its plan to cover out-of-pocket expenses of Medicare patients for drugs costing $225,000 a year to treat a rare heart condition after federal officials found that the drugmaker's arrangement could amount to illegal kickbacks.The justices took up Pfizer's appeal of a lower court's ruling that agreed with the government's view that the company's proposal to directly cover cost-sharing co-payments required of patients to use its Vyndaqel and Vyndamax drugs could violate a federal law called the Anti-Kickback Statute.New York-based Pfizer's medication, also known as tafamidis, treats a rare heart condition known as transthyretin amyloid cardiomyopathy that can lead to progressive heart failure.The U.S. Department of Health and Human Services' Office of Inspector General in 2020 concluded that the proposal could violate the kickback law by inducing patients to buy Pfizer's drug while leaving taxpayers to bear the costs.The Manhattan-based 2nd U.S. Court of Appeals last July ruled in favor of the government, rejecting Pfizer's argument that a subsidy program would violate the anti-kickback law only if it were administered with corrupt intent."